10-K: Certara's 2024 Annual Report: Biosimulation Leader Navigates Growth and Strategic Shifts

Certara's 2024 annual report highlights its position as a leader in biosimulation, focusing on growth strategies, financial performance, and strategic considerations including a review of its regulatory services business.

Summary

• Certara's 2024 annual report outlines the company's role as a global leader in biosimulation technology and solutions for Model-Informed Drug Development (MIDD).
• The company's goal is to enable the life sciences industry to use data, modeling, and analytics to make better decisions during drug development and commercialization, aiming to increase productivity and reduce costs.
• Certara's software and scientists incorporate modern advances in scientific understanding, drug development experience, data analysis, and AI, resulting in opportunities to decrease costs and increase the odds of new drug approval and commercial success.
• The company's proprietary biosimulation platforms are built on biology, chemistry, and pharmacology principles with proprietary mathematical algorithms that model how medicines and diseases behave in the body.
• Certara's customers have received 90% or more of all novel drug approvals by the U.S. Food and Drug Administration (the FDA) from 2014 through 2024.
• The company has worked with more than 2,400 life sciences companies and academic institutions and has collaborated on more than 9,000 customer projects in the last decade.
• Certara's software products are licensed by more than 94,000 users and are also used by 23 global drug regulatory agencies.
• In 2024, Certara acquired Chemaxon, a software company that develops leading software products for chemical property prediction, search, and analysis.
• The company is reviewing long-term strategic options for its regulatory services business.
• Revenue increased by 9% to $385.1 million for the year ended December 31, 2024.
• The company had cash and cash equivalents of $179.2 million as of December 31, 2024.
• As of December 31, 2024, the company had $298.5 million in total borrowings under its credit agreement and $100.0 million of capacity outstanding under its revolving credit facility.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue increased, the company reported a net loss and is evaluating strategic options for its regulatory services business. The company is a leader in its field and is growing, but there are also risks and uncertainties.

Positives

• Certara is a global leader in biosimulation technology and solutions for Model-Informed Drug Development (MIDD).
• Certara's customers have received 90% or more of all novel drug approvals by the FDA from 2014 through 2024.
• The company has worked with more than 2,400 life sciences companies and academic institutions and has collaborated on more than 9,000 customer projects in the last decade.
• Certara's software products are licensed by more than 94,000 users and are also used by 23 global drug regulatory agencies.
• In 2024, Certara acquired Chemaxon, a software company that develops leading software products for chemical property prediction, search, and analysis.
• Revenue increased by 9% to $385.1 million for the year ended December 31, 2024.

Negatives

• The company is reviewing long-term strategic options for its regulatory services business.
• Net loss was $12.1 million for the year ended December 31, 2024.

Risks

• Deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development could reduce demand.
• The market is competitive and highly fragmented.
• Changes or delays in government regulation could decrease the need for some services.
• Reduction in R&D spending by customers may reduce demand.
• Consolidation within the biopharmaceutical industry may reduce the pool of potential customers.
• Failure to retain key personnel or recruit additional qualified personnel could harm the business.
• Cybersecurity breaches or unauthorized access to data could lead to significant liabilities and loss of customer confidence.
• The company's indebtedness could materially adversely affect its financial condition and ability to operate.

Future Outlook

The company aims to release new software, additional features, and upgrades on a frequent and regular basis, with a focus on cloud-based solutions, as a means to integrate and connect access to our products within an end-to-end platform.

Management Comments

• The science, technology, and data behind biosimulation continue to advance rapidly, and our top investment priority is to develop additional functionality and uses for biosimulation to improve decision making and patient outcomes.

Industry Context

The biopharmaceutical industry is facing increasing pressure to reduce costs and improve the success rate of drug development, leading to greater adoption of innovative approaches like biosimulation.

Comparison to Industry Standards

• Certara competes with other technology companies including Mathworks, Dassault Systemes, Ansys, Simulations Plus, and NONMEM, a division of ICON.
• Other competitors include open-sourced solutions such as R and PK-Sim and internally developed software from biopharmaceutical companies.
• Certara's technology-enabled services generally compete with in-house teams at biopharmaceutical companies.
• Additionally, it competes with other specialized service providers including Metrum Research, qPharmetra, and Pharmetheus.

Stakeholder Impact

• Shareholders: The company's financial performance and strategic decisions will impact shareholder value.
• Employees: The company's growth and strategic shifts will affect employment opportunities and job security.
• Customers: The company's solutions aim to improve drug development and commercialization, ultimately benefiting patients.
• Suppliers: The company's operations and acquisitions will impact its relationships with suppliers.
• Creditors: The company's financial performance will affect its ability to meet its debt obligations.

Next Steps

• Continue to innovate in biosimulation.
• Develop more AI-enabled offerings across the portfolio.
• Engage with regulatory agencies.
• Land and expand customer relationships.
• Attract and hire specialized talent and acquire complementary businesses to expand offerings.

Key Dates